

1 **Clinical validation of pneumatic transportation** 2 **systems for monoclonal antibodies**

3 Pierre Coliat^{1*}, Stéphane Erb^{2,3,4}, Hélène Diemer^{2,3,4}, Dan Karouby¹, Mainak Banerjee¹, Chen
4 Zhu¹, Martin Demarchi¹, Sarah Cianférani^{2,3,4#}, Alexandre Detappe^{1,2,3#}, Xavier Pivot^{1#}

5 1. Institut de Cancérologie Strasbourg Europe, Strasbourg, France

6 2. Institut Pluridisciplinaire Hubert Curien, CNRS UMR7178, Université de Strasbourg,
7 Strasbourg, France

8 3. Institut du Médicament Strasbourg, Strasbourg, France

9 4. Infrastructure Nationale de Protéomique ProFI – FR2048, Strasbourg, France

10

11 * Corresponding author:

12 Pierre COLIAT (p.coliat@icans.eu)

13 ICANS, 17 Rue Albert Calmette - Strasbourg

14 # contributed equally

15

16 Keywords: pneumatic tube system, stressed antibodies, stability

17

18 Word count: 4079 words

19

20 **Abstract:** Pneumatic transportation systems (PTS) were recently proposed as a method to carry
21 ready-for-injection diluted monoclonal antibodies (mAbs) from the pharmacy to the bedside of
22 patients. This method reduces transportation time and improves the efficiency of drug distribution
23 process. However, mAbs are highly sensitive molecules for which subtle alterations may lead to
24 deleterious clinical effects. These alterations can be caused by various external factors such as
25 temperature, pH, pressure, and mechanical forces that may occur during transportation. Hence, it
26 is essential to ensure that the mAbs transported by PTS remain stable and active throughout the
27 transportation process. This study aims to determine the safety profile of PTS to transport 11
28 routinely used mAbs in a clinical setting through assessment of critical quality attributes (CQA)
29 and orthogonal analysis. Hence, we performed aggregation/degradation profiling, post-
30 translational modifications identification using complementary mass spectrometry-based
31 methods, along with visible and subvisible particle formation determination by light absorbance
32 and dynamic light scattering measurements. Altogether, these results highlight that PTS can be
33 safely used for this purpose when air is removed from the bags during preparation.

34 Introduction

35 Over the past two decades, numerous therapeutic breakthroughs in oncology have been achieved
36 with monoclonal antibodies (mAbs). These mAbs were developed and approved either as
37 modulators of the oncogenic signaling pathway by targeting overexpressed receptors (e.g.
38 trastuzumab and pertuzumab for ErbB2, cetuximab and panitumumab for ErbB1), as a trap of
39 soluble ligands involved in angiogenesis (bevacizumab for VEGFA), or as immunomodulators by
40 inhibiting immune checkpoints (pembrolizumab, atezolizumab, nivolumab, avelumab, and
41 durvalumab for the PD-1/PD-L1 pathway, ipilimumab for the CTLA-4 pathway).

42 Unlike conventional small molecule chemotherapies, the intricate structures of mAbs make them
43 susceptible to chemical modifications under conditions of chemical or physical stress¹. Among
44 chemical instabilities, methionine, histidine, and cysteine are known to cause changes in protein
45 structure, potentially leading to oxidation and the formation of disulfide bonds². Presence of
46 deamidation of glutamine and asparagine can induce changes in the structure of the protein; as a
47 result, the fragmentation of disulfide bonds may dissociate the mAbs structure and lead to an
48 inactive product³.

49 The physical instabilities are mainly characterized by reversible and nonreversible aggregations
50 due to weak nonspecific bond formation¹. For those reasons, manufacturers need to perform
51 extensive stability studies on the final product as well as on its diluted version which is specifically
52 prepared for injection in a clinical setting to attain authorization for routine usage from regulatory
53 agencies; these guidelines are well established and comparable worldwide^{4,5}. Diluted mAbs
54 products may undergo changing conditions; the reconstituted product contains lower
55 concentrations of stabilizers (*i.e.*, polysorbate 20, polysorbate 80) and additional excipients in the
56 solvent (*i.e.*, sodium chloride or dextrose). Thus, the manufacturers recommend that the product
57 is administered within 24h after the dilution to minimize the risk of mAbs being altered.; In this
58 study, the container is a plastic bag instead of a glass vial which exhibits a wider air-liquid interface

59 that may induces aggregates and the formation of visible/subvisible particles due to the shaking
60 of the container during transportation⁶. In addition, several studies have demonstrated that the
61 lack of PS20 or PS80 increases the adhesion and aggregation of mAbs to the plastic bag in
62 polyvinylchloride (PVC) or polyolefin⁷⁻⁹. These 2 major mAbs modifications are considered risks,
63 as they may lead to immunogenicity¹⁰. The key critical quality attributes (CQAs) of mAbs, including
64 the protein structure or the glycosylation profile, can be altered but cause a risk of altered activity
65 and/or toxicity^{11,12}; thus the conditions of preparation for mAbs must be considered with caution to
66 ensure that the administrated therapy is safe and effective.

67 One of the most common feature present in all major hospitals is the presence of pneumatic
68 transportation systems (PTS). They were originally developed to accelerate the transportation
69 biological samples from one floor to another. More recently, they were deployed for the
70 transportation of anticancer therapies. According to each country, the regulations supporting the
71 routine use of PTS vary from a definitive prohibition guided by precautionary principles due to the
72 lack of robust evidence to a systematic utilization. These variable approaches and discrepancies
73 in the routine use of PTS occur because of the external stress applied to these mAbs during
74 transportation as they undergo acceleration and deceleration of multiple g forces as well as radical
75 gravity forces. Here, we sought to determine the possible alterations that occur in terms of CQA
76 to qualify the routine use of PTS with 11 mAbs approved for clinical use in oncology by the
77 European Medicines Agency (EMA).

78

79

80 **Results:**

81 **Characteristics of the PTS.** The PTS from the Institut de Cancérologie Strasbourg Europe
82 (ICANS) is an Aerocom AC4000 160mm millimeters, 1000m long and includes approx. 20 curves
83 (**Figure 1A-B**). The cartridge used to transport the mAbs along the different departments from the
84 institution undergoes an acceleration profile of $4.06 \pm 1.75g$ *per* travel with more than 15
85 acceleration peaks of $>20g$ *per* travel and a maximum at 32g that is reached 4 times (**Figure 1C**).
86 For this study, we placed the diluted mAbs inside the cartridge; the mAbs went through the whole
87 tube 1x to characterize the institution setup and 10x to generalize the results to almost any PTS
88 system installed in Europe using the same technical features.

89
90 **Aggregation analysis.** We assessed the potential aggregation by characterizing the high
91 molecular weight species (HMWS) and the degradation products by assessing the low molecular
92 weight species (LMWS) by size-exclusion chromatography coupled to native mass spectrometry
93 (SEC-nMS), a method that accurately quantifies HMWS/LMWS from SEC along with mass
94 identification of each species within the same analysis^{13,14}. The SEC-nMS was used to evaluate
95 the HMWS and LMWS contained in the reference mAbs (non-diluted, in glass vial), post thermal
96 stress (20 days 40°C, non-diluted, in glass vial, see material and methods), and for the diluted
97 product passed 1-time in the PTS. We highlighted the results obtained with the mAb pertuzumab;
98 these results will be used as case study throughout the manuscript, additional mAbs are presented
99 as bar graphs. The SEC-nMS reveals 3 peaks corresponding to the main monomeric drug product
100 (peak 2, MW $148,095 \pm 2$ Da, 99.8%), minor dimeric HMWS (peak 1, $< 0.1\%$) and Fc-Fab LMWS
101 (peak 3, $< 0.1\%$). Samples after 1 PTS passage exhibit superimposable SEC-UV and nMS profiles
102 to the one of reference samples, while thermally stressed samples show significantly higher
103 amounts of both HMWS (dimers, 0.9%, $p=0.027$) and LMWS ($100,941 \pm 7$ Da for Fc-Fab and
104 $47,650 \pm 2$ Da for Fab fragments, 3.5% in total; $p=0.0104$) (**Figure 2A-B**).

105 For all mAbs, the main observed peak was attributed to the monomeric mAb drug product
106 highlighting high levels of purity for reference mAbs (> 99.5%, **Figure 2C**). Only very minor species
107 corresponding to the mAb aggregates (dimers ~300 kDa, < 0.3%) and fragments (Fab fragment
108 ~47 kDa, < 0.1%) were quantified from SEC-UV data and online identified by nMS. Only two mAbs
109 (panitumumab and bevacizumab) showed a higher content of HMWS (~1.1-1.2%) (**Figure 2C**),
110 which is in agreement with literature data¹⁵.

111 After 1 PTS passage, chromatographic profiles were not significantly different from those of
112 reference samples, and the drug substance being detected as main product (> 99.5%) with minor
113 HMWS (<0.3%) and LMWS (<0.1%). The overall degradation profile was strongly affected upon
114 thermal stress (higher HWMS and/or LMWS) independently of the 11 mAb compared to PTS and
115 reference samples, confirming that the thermal stress should be used as positive control for mAb
116 degradation¹⁶. Of interest, panitumumab, bevacizumab, trastuzumab, cetuximab and pertuzumab
117 are significantly less stable under thermal stress, leading to either higher amounts of HMWS (>
118 3%, panitumumab and bevacizumab) or LMWS (>2%, trastuzumab, pertuzumab, bevacizumab
119 and cetuximab).

120 Altogether, this study was performed with 11 diluted mAbs and demonstrated that neither
121 reference mAbs, nor samples were degraded with one PTS passage in contrast to thermally
122 stressed samples. They all exhibit comparable amounts of monomeric drug product (main peak),
123 HMWS, and LMWS species confirming the safety profile of the PTS system from the ICANS
124 institution. Similar results were obtained after 10 passages in the PTS for trastuzumab (**Figure**
125 **S1**) confirming its safety profile.

126
127 **Glycoprofiles and post translational modifications (PTMs)**. We next focused on glycoprofiles
128 and some important PTMs which were defined as CQA (oxidations, N-terminal pyroglutamylation

129 and C-terminal lysine deletion) to further examine the impact due to PTS at the molecular level.
130 We combined complementary LC-MS methods in either native (SEC-nMS) or denaturing
131 (reversed-phase liquid chromatography, rpLC-MS) conditions at both intact mAb and subunit
132 levels (after IdeS digestion) to avoid extensive time-consuming peptide mapping (**Figure 3**).

133 Glycosylation is among the most common PTM that can induce tremendous effects on the
134 physicochemical properties, structure, and function of mAbs therapeutic efficiency¹⁷. The
135 glycoprofile can affect the absorption distribution metabolism elimination (ADME) properties
136 and the biosimilarity of the glycoprotein-based drugs by altering the PK profile¹⁸, receptor binding,
137 and antibody dependent cell cytotoxicity (ADCC)¹⁹. Currently, MS-based techniques are widely
138 used for the analysis of mAb heterogeneity of glycosylation^{20,21}.

139 Glycoprofiles were first investigated using SEC-nMS on intact reference mAbs, after one PTS
140 passage and after thermal stress. The overlaid deconvoluted native mass spectra of the 3 different
141 pertuzumab samples (diluted, PTS, thermally stressed) demonstrates perfectly superimposable
142 glycoprofiles at the intact level and unambiguous mass identification of the main glycovariants
143 (G0F/G0F, G1F/G0F, G1F/G1F and G2F/G1F) (**Figure 3A-B**). No peak broadening is observed
144 for the PTS samples in comparison to reference mAb conversely to thermally stressed samples.
145 Among the 10 mAbs studied (atezolizumab being a-glycosylated), only cetuximab glycoprofiling
146 could not be tackled by SEC-nMS, in agreement with this mAb bearing two glycosylation sites^{22,23}.

147 No significant glycoprofiles differences were observed for any of the samples in the different
148 conditions (reference, PTS or thermally-stressed; $p>0.05$) (**Figure 3C**).

149 To cross validate the SEC-nMS results, the middle-up analysis of all mAbs were performed after
150 IdeS digestion using a more classical high resolution rpLC-MS method on ~25 kDa subunits²⁴.

151 Three main peaks are observed for pertuzumab, corresponding to Fc/2 (peak 2, 25236 Da), LC
152 (peak 3, 23526), and Fd (peak 3, 25315) subunits respectively. The Fc/2 part bearing the N-
153 glycosylation pattern (Man5, G0F-GlcNAc, G0, G0F, G1F, G2F) (**Figure 4**). The rpLC

154 chromatogram of reference and PTS samples present similar patterns, whereas the peak 1 is
155 more intense in the thermally stressed sample. Similar to the intact mass analysis, Fc/2
156 glycoprofiles of reference versus PTS or temperature stressed samples overlay perfectly.

157 The glycoprofiles observed for all 10 other mAbs were non-significantly different (**Figure 5**),
158 suggesting that the glycoprofiles are not significantly affected upon PTS passage ($p>0.05$).
159 Interestingly, bevacizumab undergoes loss of GOF upon thermal stress. This result is in
160 accordance with knowledge that this mAb is more prone to stress conditions than other mAbs.

161
162 **K-clipping.** The presence/absence of C-terminal lysine (K-clipping) in the heavy chain (Fc
163 fragment) is another common CQA that reflects the manufacturing consistency. This modification
164 can be assessed by rpLC-MS at the middle level as it generates a mass shift of ~128 Da (K
165 clipping/deletion variant) and a more hydrophobic variant. Among the 11 mAbs studied, rpLC-MS
166 analysis of the Fc subunit revealed that all of them are formulated in their fully K-clipped versions
167 (>95%, total Fc-K species, **Table 3**), while proteoforms containing the C-terminal lysine
168 representing <5% in diluted mAb samples (**Table 3**). Cetuximab and avelumab are examples of
169 mAbs exhibiting mixtures of K-clipped (~75%) and non-K-clipped (~25%) forms. Importantly, the
170 ratio of K-clipped/K-containing species remains unchanged after 1 PTS passage (**Table 3**). Similar
171 conclusions can be drawn from thermally stressed samples, suggesting that deletion of C-terminal
172 lysine is stable once generated from the production process and not significantly impacted upon
173 any of the stress conditions.

174
175 **Oxidation.** Oxidation is an important CQA that impacts the structural integrity, conformational
176 stability, safety, and efficacy of the mAb product²⁵. While no negative impacts have been reported
177 for the oxidation present on complementary determining regions (CDR) on antigen binding, many
178 negative impacts have been reported for the oxidation of Met residues in the Fc part of the mAb

179 such as decreased thermal stability, increased aggregation, decreased complement dependent
180 cytotoxicity (CDC), decreased binding affinity to neonatal Fc receptor (FcRn), and shorter in vivo
181 half-life, *etc.* We thus sought to explore to which extent PTS passages could induce mAb oxidation
182 (+16 or 32 Da mass increases), knowing that limited effects are expected as air was removed from
183 the plastic packaging. No oxidation was detected on the Fc or Fd subunits of the reference mAbs,
184 at the exception of atezolizumab and bevacizumab for which traces were observed (<3%, **Table**
185 **3**). Importantly, these levels were not affected post PTS passage, but were observed for the
186 thermally stressed mAbs (e.g. atezolizumab Fd, bevacizumab Fc+Fd, **Table 3**).

187
188 **Pyro-Glu.** N-terminal pyroglutamate (pyroGlu) is a common mAb modification that mainly results
189 from a non-enzymatic cyclization of N-terminal glutamine (Gln) or to a much lower extent from the
190 conversion of N-terminal glutamate (Glu) into pyroGlu²⁶. Cyclization of N-terminal Gln/Glu to
191 pyroGlu reduces the molecular weight of a mAb by 17 Da or 18 Da, respectively and induces more
192 acidic variants compared to original non-N-terminally modified mAbs²⁰. However, the presence of
193 N-terminal pyroGlu exhibits no direct impact on mAb structure and function. As levels of N-terminal
194 pyroGlu observed in mAbs vary strongly with various environmental factors (buffer composition,
195 pH, temperature during cell culture and purification, *etc.*), we next investigated the N-terminal
196 cyclization on the Fd subunit of the 11 mAbs (**Table 3**). Half of them were formulated as non-
197 pyroGlu forms and very low levels (<3%) of pyroGlu modification on the N-terminal part of our
198 mAbs were detected. At the opposite, the other mAbs are formulated as pyroglutamylated forms
199 (>93%, **Table 3**), except for panitumumab formulated as a mixture of unmodified (21%) and N-
200 terminal pyroGlu (79%) forms. No significant changes were detected after PTS passage, while
201 increased level of pyroGlu forms are systematically observed upon thermal stress (**Table 3**).

202

203

204 **Visible and subvisible particles assessment.** Turbidity was investigated by measuring the
205 absorbance at 3 different wavelengths. Comparable relative absorption variations were observed
206 between all conditions which was consistent with the lack of visible foam in the bags as determined
207 by visual inspection (**Table 4**). Subvisible particle formation was then analyzed by dynamic light
208 scattering (DLS) measurements with the same stress conditions applied to the mAbs (control in
209 glass vial, control in plastic bag, thermal stress, and PTS). For the 4 mAbs studied (pertuzumab,
210 pembrolizumab, trastuzumab, and cetuximab), we observed small (5-20 nm) and large (1-10 μm)
211 particles in all conditions tested (**Figure 6**). Our observations indicate that thermally stressed
212 conditions led to a higher abundance of large particles, while no significant differences were
213 observed between the control groups and the PTS conditions. We also observed a third population
214 of particles, ranging from 100-200 nm for each mAb, exclusively in the thermally stressed group.

215

216 **Discussion and conclusion**

217 Quality issues due to biologics were highlighted by the development of trastuzumab biosimilars
218 where batch-to-batch differences of the reference product were monitored over a long-term period
219 of time to assess the ranges of variations for key CQAs²⁷⁻²⁹. A modification of the glycosylation
220 profile was observed; such modifications impacted the Fc γ RIIIa binding as well as the ADCC
221 activity of the mAbs without any decreasing their antiproliferative activity against the HER2-
222 positive cancer cells^{18,30}. However, in a phase III clinical trials aiming to validate the equivalence
223 between the referent trastuzumab and SB3³¹ or ABP980³², the predefined equivalence margins to
224 assess the equivalence of the primary efficacy endpoints (pathological complete response – pCR)
225 were exceeded. The results of this clinical trial suggested that a potential superiority could not be
226 ruled out. A deeper analysis of the results of the clinical trial demonstrated that the pCR rates were
227 dictated by an unexpected modification of the trastuzumab reference product for which alterations
228 of fucose and mannose levels were determined.

229 This prompted us to focus on some major CQA to assess the impact of PTS passage in our
230 institute with the final objective to develop analytical methods that could be utilized in hospitals
231 equipped with qualified LC-MS systems by focusing on methods without extensive mAb handling
232 as well as with protocols that could be automatized. Intact protein analysis with SEC-nMS was
233 selected as first line method to evaluate multiple quality attributes within a single 10 min run. The
234 SEC-nMS method allows assessment of the drug product purity with simultaneous detection,
235 quantification, and accurate mass identification of the main product (including glycoprofile
236 monitoring) along with aggregates (HMWS) and fragments (LMWS) identification. For more
237 precise analysis of CQA related to important PTMs (glycosylation, oxidation, pyroglutamylation,
238 and C-terminal K cleavage), complementary rpLC-MS analyses of IdES downsized mAb subunits
239 were performed. Altogether, the intact- and middle-level analytical pipelines demonstrated that
240 PTS did not induced major changes both in terms of size variants and for a selected series of
241 charge variants.

242 This work suggests that compared to bottom up workflows (peptide mapping), which are more
243 difficult to envision in a QC laboratory of a hospital, intact- and middle- level LC-MS analysis could
244 be proposed as “multiple attribute monitoring” methods in regulatory environments like hospital for
245 routine analysis. The external stress induced by PTS on a mAb in its diluted version potentially
246 represents a more sensitive condition gathering high risks regarding the preservation of the
247 integrity of the drug product. Hence, the orthogonal analysis of the 11 mAbs diluted in a version
248 ready to be injected to patients demonstrated the absence of observed impact induced by the PTS
249 as analyzed with the major CQA methods (HMWS, LMWS, glycoform profile, oxidation, etc). A
250 comparable aggregation/degradation status and absence of alterations addressing the protein
251 primary structure, the glycosylation profile, the oxidation level, N-terminal cyclization and C-
252 terminal K cleavage along with identical particle sizes were observed in the PTS.

253 A key confounding factor related to the risk assessment is whether air is removed from the plastic
254 bag. Indeed, here, at the opposite to what was previously performed⁶, the air was removed from
255 the plastic bag to reduce as much as possible the air-liquid interface to minimize the risks of
256 oxidations. This modification in the preparation method before using the PTS seems to be the
257 most important factor to justify using the PTS to transport the mAbs in a routine environment.
258 Hence, through the evaluation of the 11 mAbs, the PTS did not modify any of the mAbs. However,
259 caution should be considered to extend these results to PTS at every hospital without previous
260 assessment of the configuration of their transportation system. If the PTS configuration highly
261 differs from ours, a case-by-case quality control of the PTS should be recommended.
262 Nevertheless, the results obtained with 1 passage and 10 passages providing comparable
263 findings, it is safe to assume that PTS should not induce modification of the mAbs in respect to
264 the CQA if the air-liquid interface is reduced at the minimum level.

265

266

267 **Material and methods**

268 **Materials.** A total of 11 mAbs were obtained from the commercial final products provided by the
269 ICANS hospital pharmacy. Three different batches of each one, with the 3 defined conditions,
270 were used for the analysis following orthogonal methods for different critical quality attributes
271 (CQAs) (Table 1 and 2).

272 **Reference mAbs.** Commercially non-diluted mAbs stored in their original glass packaging were
273 used for analysis with 3 different batches.

274 **Pneumatic stress condition.** Each batch was diluted in a prefilled sodium chloride polyolefin
275 (PO) bag at a concentration of 1 mg/ml. The air was removed after dilution limiting the impact of
276 the air-water interface. The bags were then placed in the pneumatic cartridge and underwent one
277 trip through the PTS (Aerocom AC4000; Krautergersheim, France) before analysis.

278 **Thermal stress condition.** Each batch, at commercial concentration, was incubated at 50°C
279 during 20 days in the original glass vial before analysis to generate the thermal stress.

280 **Acceleration measurements.** As a qualification process for the PTS, we have established a
281 cartography of stress constraints induced during the transport. An accelerometer (Volcraft® DL-
282 131g, Hirschau, Germany) was fixed into a plastic bag in the cartridge used over a PTS
283 transportation. A total of 10 travels were performed providing a characterization of all forces
284 induced by the PTS on the bag. The average speed of the cartridge was fixed at 3.5m/s.

285 **SEC-nMS.** An ACQUITY UPLC H-class system (Waters, Manchester, UK) comprising a
286 quaternary solvent manager, a sample manager cooled at 10 °C, a column oven maintained at
287 room temperature and an UV detector operating at 280 nm and 214 nm hyphenated to a Synapt
288 G2 HDMS mass spectrometer (Waters, Manchester, UK) was used for the online SEC-native MS
289 instrumentation. Forty micrograms of mAb were loaded on the ACQUITY UPLC Protein BEH SEC
290 column (4.6 x 150 mm, 1.7 µm particle size, 200 Å pore size) from Waters (Manchester, UK) using

291 an isocratic elution of 100 mM ammonium acetate (NH₄OAc) at pH 6.9 with the following flow rate
292 gradient : 0.250 mL/min over 3.0 minutes, then 0.100 mL/min from 3.1 to 15.0 minutes, and finally
293 0.250 mL/min from 15.1 to 18.0 minutes.

294 The Synapt G2 HDMS was operated in positive mode with a capillary voltage of 3.0 kV while
295 sample cone and pressure in the interface region were set to 180 V and 6 mbar, respectively.
296 Acquisitions were performed in 50–15,000 m/z range with a 1.5 s scan time. The mass
297 spectrometer was calibrated using singly charged ions produced by a 2 g/L solution of cesium
298 iodide (Acros organics, Thermo Fisher Scientific, Waltham, MA USA) in 2-propanol/water (50/50
299 v/v). Native MS data interpretations were performed using Mass Lynx V4.1 (Waters, Manchester,
300 UK).

301 Relative quantification of HMWS/LMWS by intact SEC-native was performed using the relative
302 abundances calculated from the areas of the chromatographic peaks obtained at 280 nm. For the
303 quantification of glycoforms at intact levels, the relative abundances were based on the intensities
304 obtained after deconvolution of the mass spectrum. Standard deviations were calculated using
305 biological replicates.

306
307 ***Middle level analysis using rpLC-MS.*** Enzymatic digestion (FabRICATOR®, Genovis, Sweden)
308 was performed by incubating one unit of IdeS protease per microgram of mAb. First of all, the
309 enzyme was reconstituted at four units per microliter in ultrapure water. Then, the corresponding
310 volume was added to fifty micrograms of mAb. The total volume was completed at seventy
311 microliters by adding a buffer composed of 50 mM Na₂HPO₄ and 150 mM NaCl at pH 6.7. Finally,
312 the mixture was incubated at 37 °C for thirty minutes under shaking (500 rpm). In order to perform
313 a strong denaturation, thirty-three milligrams of guanidine HCl (powder) was directly added to the
314 mixture. The reduction step was performed by adding ten microliter of TCEP (tris(2-

315 carboxyethyl)phosphine) solution at 560 mM. After sixty minutes incubation at 57 °C under shaking
316 (500 rpm), the reaction was quenched by adding one microliter of TFA (trifluoroacetic acid)
317 solution. LC-MS analyses were performed using an Agilent 1200 series coupled to a maXis II
318 (Bruker) Q-TOF based mass spectrometer. A volume equivalent to five micrograms of sample
319 preparation was injected on a BioResolve™ RP mAb 2.1 mm internal diameter and 150 mm
320 length, pore size 450 Å and particle size 2.7 µm, polyphenyl column (Waters, Manchester, UK)
321 set at 80 °C. The UV chromatogram was acquired with a DAD detector operating from 200 to 400
322 nm. Ultrapure water for mobile phase A (0.10% TFA) and acetonitrile for mobile phase B (0.08%
323 TFA) were used to perform the chromatographic separation. The gradient was generated at a flow
324 rate of 300 µL/min and the elution program started at 25% mobile phase B during two minutes to
325 reach 44% in thirty-eight minutes. Then, five minutes of washing step at 75% and finally fourteen
326 minutes of equilibration at 25% mobile phase B. A blank was injected between each sample under
327 the same conditions. The mass spectrometer was operated in positive mode with a capillary
328 voltage of 4,500 V and CID value was set at 70 eV. Acquisitions were performed on the mass
329 range 500-3,000 m/z. Calibration was performed using the singly charged ions produced by a
330 solution of 2 g/L caesium iodide in 2-propanol/water (50/50 v/v). Data interpretation was performed
331 by using Compass DataAnalysis 4.3 software (Bruker Daltonics). Since the molecular isotopic
332 cluster was not fully resolved, average molecular masses were measured.

333 Relative quantification of PTMs identified from middle level rpLC-MS analysis was performed
334 using the relative abundances calculated from the areas of the chromatographic peaks obtained
335 at 280 nm. For the quantification of glycoforms at the middle level, the relative abundances were
336 based on the intensities obtained after deconvolution of the mass spectrum. Standard deviations
337 were calculated using biological replicates.

338

339 **Visible particles.** Absorbance was measured with a spectrophotometer (UV-1800, Shimadzu) at
340 340, 410 and 550nm for each condition (control diluted in PO bag, pneumatic stress condition with
341 one travel through the PTS, and thermal stress condition). Absorbance measurements were
342 performed by aliquoting 1 ml of each sample and were expressed relative to the blank condition
343 (sodium chloride in PO bag). A visual inspection of each bag transported with the PTS system
344 was also implemented to detect foam.

345
346 **Subvisible particles.** The mAbs were stored under 3 different conditions (control in vials,
347 pneumatic stress condition with one trip through the PTS, and thermal stress condition) and then
348 the effect of these conditions on their size was evaluated by analyzing dynamic light scattering
349 (DLS) measurements (Amerigo Particle Size Analyzer, Cordouan Technologies). The DLS
350 measurements were performed by directly aliquoting the samples into a cuvette exposed to an
351 external laser of 638 nm. The raw data were further analyzed by using the sparse Bayesian
352 learning (SBL) algorithm and then the intensity average number of particles was plotted on
353 Graphpad Prism 8.0.

354
355 **Statistical analysis.** To evaluate significant differences between the reference monoclonal
356 antibody (mAb) condition and the conditions of thermal or pressure thermal shock (PTS), an
357 analysis of variance (ANOVA) test was conducted. To further examine the differences between
358 the groups, the ANOVA test was supplemented with a Tukey test for intergroup comparisons.
359 Differences were considered statistically significant if the p-value was less than 0.05

360

361 **Acknowledgments.** This study was supported by the CNRS, the University of Strasbourg, the
362 Agence Nationale de la Recherche, the French Proteomic Infrastructure (ProFI; ANR-10-INBS-
363 08-03), the Interdisciplinary Thematic Institute IMS (Institut du Médicament Strasbourg), as part
364 of the ITI 2021-2028 supported by IdEx Unistra (ANR-10-IDEX-0002), SFRI-STRAT'US project
365 (ANR-20-SFRI-0012), and by the Institut de Cancérologie Strasbourg Europe.

366 Mass spectrometers were purchased through financial support of GIS IBiSA, Région Grand Est,
367 the IdeX initiative of the University of Strasbourg and the French National Proteomic Infrastructure.

368 Authors would like to acknowledge the fruitful discussion with Aerocom^{ltd} (Krautergersheim,
369 France) about their PTS system which led to this research project.

370

371 **Disclosure of Interest:** None.

372 **Author contributions:**

373 Pierre Coliat have full access to all the data in the study and take responsibility for the integrity of
374 the data and accuracy of the data analysis.

375 Concept and design: Pierre Coliat, Martin Demarchi, Xavier Pivot, Alexandre Detappe, Sarah
376 Cianférani

377 Supervision: Pierre Coliat, Sarah Cianférani, Alexandre Detappe

378 Statistical analysis: Pierre Coliat, Sarah Cianférani

379 Administrative, technical, or material support: Dan Karouby, Stéphane Erb, Hélène Diemer

380 Acquisition, analysis, and interpretation of data: Pierre Coliat, Alexandre Detappe, Stéphane Erb,
381 Hélène Diemer, Mainak Banerjee, Chen Zhu

382 Manuscript draft: Pierre Coliat, Sarah Cianférani

383 Critical revision of the manuscript for important intellectual content and approval: Pierre Coliat,
384 Alexandre Detappe, Dan Karouby, Stéphane Erb, Hélène Diemer, Mainak Banerjee, Chen Zhu,
385 Martin Demarchi, Sarah Cianférani, Xavier Pivot

386
387 **Role of the funder/Sponsor:** The academic funding source (ICANS) validated the study as
388 designed by the trial's steering committee. The data were interpreted by the trial's steering
389 committee independently of the sponsor. The sponsor approved the manuscript and agreed to
390 submit it for publication.

391

392 **References**

- 393 1. Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A. & Sautou, V. Physicochemical Stability of
394 Monoclonal Antibodies: A Review. *J. Pharm. Sci.* **109**, 169–190 (2020).
- 395 2. Mahler, H.-C., Friess, W., Grauschopf, U. & Kiese, S. Protein aggregation: Pathways, induction
396 factors and analysis. *J. Pharm. Sci.* **98**, 2909–2934 (2009).
- 397 3. Vlasak, J. & Ionescu, R. Fragmentation of monoclonal antibodies. *mAbs* **3**, 253–263 (2011).
- 398 4. FDA. Q1A(R2)-Stability-Testing-of-New-Drug-Substances-and-Products.pdf.
- 399 5. EMEA. <1049> *Quality of Biotechnological Products: Stability Testing of*
400 *Biotechnological/Biological Products*. https://doi.usp.org/USPNF/USPNF_M99771_01_01.html
401 [doi:10.31003/USPNF_M99771_01_01](https://doi.org/10.31003/USPNF_M99771_01_01).
- 402 6. Linkuvienė, V. *et al.* Effects of Transportation of IV Bags Containing Protein Formulations Via
403 Hospital Pneumatic Tube System: Particle Characterization by Multiple Methods. *J. Pharm. Sci.*
404 **111**, 1024–1039 (2022).
- 405 7. Morar-Mitrica, S. *et al.* Development of a stable low-dose aglycosylated antibody formulation to
406 minimize protein loss during intravenous administration. *mAbs* **7**, 792–803 (2015).

- 407 8. Smith, C. *et al.* Antibody adsorption on the surface of water studied by neutron reflection. *mAbs*
408 **9**, 466–475 (2017).
- 409 9. Lefebvre, G. *et al.* Surfactant Protection Efficacy at Surfaces Varies with the Nature of
410 Hydrophobic Materials. *Pharm. Res.* **38**, 2157–2166 (2021).
- 411 10. Moussa, E. M. *et al.* Immunogenicity of Therapeutic Protein Aggregates. *J. Pharm. Sci.*
412 **105**, 417–430 (2016).
- 413 11. Wolf, B. *et al.* Therapeutic antibody glycosylation impacts antigen recognition and
414 immunogenicity. *Immunology* **166**, 380–407 (2022).
- 415 12. E. Lundahl, M. L., Fogli, S., E. Colavita, P. & M. Scanlan, E. Aggregation of protein
416 therapeutics enhances their immunogenicity: causes and mitigation strategies. *RSC Chem.*
417 *Biol.* **2**, 1004–1020 (2021).
- 418 13. Etker, A. *et al.* Hyphenation of size exclusion chromatography to native ion mobility mass
419 spectrometry for the analytical characterization of therapeutic antibodies and related products.
420 *J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.* **1086**, 176–183 (2018).
- 421 14. Habegger, M. *et al.* Rapid characterization of biotherapeutic proteins by size-exclusion
422 chromatography coupled to native mass spectrometry. *mAbs* **8**, 331–339 (2015).
- 423 15. Oliva, A., Llabrés, M. & Fariña, J. B. Fitting bevacizumab aggregation kinetic data with the
424 Finke–Watzky two-step model: Effect of thermal and mechanical stress. *Eur. J. Pharm. Sci.* **77**,
425 170–179 (2015).
- 426 16. Goyon, A. *et al.* Characterization of 30 therapeutic antibodies and related products by size
427 exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
428 *J. Chromatogr. B* **1065–1066**, 35–43 (2017).
- 429 17. Delobel, A. Glycosylation of Therapeutic Proteins: A Critical Quality Attribute. *Methods Mol.*
430 *Biol. Clifton NJ* **2271**, 1–21 (2021).
- 431 18. Liu, L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. *Protein Cell* **9**,
432 15–32 (2018).

- 433 19. Van Coillie, J. *et al.* Role of N-Glycosylation in FcγRIIIa interaction with IgG. *Front.*
434 *Immunol.* **13**, (2022).
- 435 20. Beck, A. & Liu, H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG
436 Antibodies. *Antibodies* **8**, 18 (2019).
- 437 21. De Leoz, M. L. A. *et al.* NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal
438 Antibodies: Comparison of Results from Diverse Analytical Methods. *Mol. Cell. Proteomics*
439 *MCP* **19**, 11–30 (2020).
- 440 22. Beck, A. *et al.* Cutting-edge mass spectrometry characterization of originator, biosimilar
441 and biobetter antibodies. *J. Mass Spectrom.* **50**, 285–297 (2015).
- 442 23. Sorensen, M. *et al.* Comparison of originator and biosimilar therapeutic monoclonal
443 antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-
444 flight mass spectrometry. *mAbs* **8**, 1224–1234 (2016).
- 445 24. Chevreux, G., Tilly, N. & Bihoreau, N. Fast analysis of recombinant monoclonal antibodies
446 using IdeS proteolytic digestion and electrospray mass spectrometry. *Anal. Biochem.* **415**, 212–
447 214 (2011).
- 448 25. Gupta, S., Jiskoot, W., Schöneich, C. & Rathore, A. S. Oxidation and Deamidation of
449 Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy.
450 *J. Pharm. Sci.* **111**, 903–918 (2022).
- 451 26. Dick, L. W., Kim, C., Qiu, D. & Cheng, K.-C. Determination of the origin of the N-terminal
452 pyro-glutamate variation in monoclonal antibodies using model peptides. *Biotechnol. Bioeng.*
453 **97**, 544–553 (2007).
- 454 27. Lüftner, D., Lyman, G. H., Gonçalves, J., Pivot, X. & Seo, M. Biologic Drug Quality
455 Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the
456 Trastuzumab Biosimilar SB3. *Target. Oncol.* **15**, 467–475 (2020).
- 457 28. Planinc, A. *et al.* Batch-to-batch N-glycosylation study of infliximab, trastuzumab and
458 bevacizumab, and stability study of bevacizumab. *Eur. J. Hosp. Pharm.* **24**, 286–292 (2017).

- 459 29. Batch Variation in Trastuzumab Study Affects Outcomes. *Center for Biosimilars*
460 <https://www.centerforbiosimilars.com/view/batch-variation-in-trastuzumab-study-affects->
461 outcomes (2020).
- 462 30. Pivot, X. *et al.* Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety,
463 and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients
464 Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive
465 Early Breast Cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **36**, 968–974 (2018).
- 466 31. Pivot, X. *et al.* Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar)
467 versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor
468 receptor 2-positive breast cancer. *Eur. J. Cancer Oxf. Engl. 1990* **120**, 1–9 (2019).
- 469 32. Minckwitz, G. von *et al.* Efficacy and safety of ABP 980 compared with reference
470 trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised,
471 double-blind, phase 3 trial. *Lancet Oncol.* **19**, 987–998 (2018).
- 472
- 473


1
2 **Figures**

3




4
5 **Figure 1. Characterization of the pneumatic transportation system (PTS).** A. Map of the PTS
6 at the Institut de Cancérologie Strasbourg Europe. In red the one used for this study. B.
7 Representation of the setup used for transportation of the monoclonal antibodies (mAbs). C.
8 Characterization of the cumulative (x, y, and z axis) acceleration forces applied to the mAbs.

9



10
 11 **Figure 2 : Intact level SEC-nMS analysis. A.** Intact level SEC-nMS analysis of pertuzumab.
 12 SEC-UV chromatograms. Insert highlight the low levels of HMWS and LMWS. **B.** Summary of the
 13 masses measured for the main drug product and aggregates/fragments in the different conditions.
 14 **C.** Quantification of HMWS and LMWS from intact SEC-native MS analysis. Histograms represent
 15 SEC-UV peak area integration of aggregates (HMWS, mostly dimers) and fragments (mostly Fab-
 16 FC and Fab) for the 11 mAbs under investigation. Red : Reference mAbs ; Black : 1 pass-PTS
 17 mAbs, Grey : Thermally stressed mAbs.

18




19
 20 **Figure 3 : Glycoprofiles obtained from intact SEC-native MS analysis. A.** Deconvoluted mass
 21 spectrum of mAb drug products (main peak) revealing glycoprofiles and corresponding histogram
 22 for glycoform quantification. **B.** Summary of the masses measured for main glycoforms. **C.**
 23 Histograms represent MS peak intensities obtained after zero-charge deconvolution of the main

24 glycoforms for the 11 mAbs under investigation. Of note atezolizumab is an a-glycosylated mAb
25 and not represented, while cetuximab glycoprofile could not be resolved using intact SEC-nMS.
26 Red : Reference mAbs ; Black : 1 pass-PTS mAbs, Grey : Thermally stressed mAbs.

27


28



29

30 **Figure 4 : Middle level rpLC-MS analysis of pertuzumab.** **A.** rpLC chromatogram of
 31 pertuzumab obtained after IdeS digestion highlighting the LC, Fd and Fc/2 subunits. **B.** Summary
 32 of the masses measured for the different subunits. **C.** Deconvoluted mass spectrum and of the Fc
 33 subunit revealing similar glycoprofiles and subsequent glycoform quatification presented as
 34 histograms. **D.** Summary of the masses of the main glycoforms. Red : Reference mAbs ; Black :
 35 1 pass-PTS mAbs, Grey : Thermally stressed mAbs.


36



37

38 **Figure 5 : Glycoprofiles of the 11 mAbs after IdeS digestion and rpLC-MS analysis.** Relative
 39 quantification of the glycoforms was performed after zero-charge deconvolution of MS peaks of
 40 Fc/2 subunits. Red : Reference mAbs ; Black : 1 pass-PTS mAbs, Grey : Thermally stressed
 41 mAbs.

42



43
44 **Figure 6: Dynamic Light Scattering analysis of four stressed mAbs.** Two distinguishable
45 particle populations were observed: Small particles ranging from 5-20nm and larger particles
46 ranging from 1-10 μ m. A third population emerged under thermally stressed conditions, consisting
47 of particles ranging from 100-200nm for each monoclonal antibody.

48
49

50

Name	Commercial Name	Type	Batches					
			1st Batch (Exp)		2 nd Batch		3 rd Batch	
Atezolizumab	TECENTRIQ®	IgG1	1162031	08/21	B0014	11/22	B0016H22	03/23
Avelumab	BAVENCIO®	IgG1	213079/06	03/21	AU029984	12/21	AU030487	03/22
Bevacizumab	MVASIS®	IgG1*	N7407H03	12/21	1120891	03/22	1120893	03/22
Cetuximab	ERBITUX®	IgG1	GOOEAJ	10/23	GOOH62	12/23	GOOMS1	03/24
Durvalumab	IMFINZI®	IgG1	0121B16A	05/21	022M17B	03/23	019M17A	03/23
Ipilimumab	YERVOY®	IgG1	ABN2184	05/22	ABE3010	11/21	ABE3010	11/21
Nivolumab	OPDIVO®	IgG4	ABQ8316	06/21	ABN601	02/22	CLI10519	04/21
Panitumumab	VECTIBIX®	IgG2	1113353	06/22	1115899	06/22	1121578A	10/22
Pembrolizumab	KEYTRUDA®	IgG4	011736	11/21	T028333	01/22	T031876	02/22
Pertuzumab	PERJETA®	IgG1	H0385H02	10/21	H0437H02	07/22	H0439H05	07/22
Trastuzumab	TRAZIMERA®	IgG1	DE8014	02/20	N3021H02	09/22	DC5104	07/23

51

52 **Table 1 : Summary of antibodies tested.** We tested a total of 11 monoclonal antibodies (mAbs)
 53 using three different batches (except for ipilimumab, which was tested twice with the same batch).
 54 The analysis was conducted prior to the expiry date of each mAb.

55

Critical Quality Attributes	Methods	Assessment
Aggregation/degradation	SEC n-MS	HMWS/LMWS and monomeric pics on Intact mAbs or middle-up analysis
Identification of PTM modification	SEC-nMS RPLC-MS	Glycovariants Deamidation, oxydation, disulfide bond analysis
Turbidity	UV/visible spectrophotometer	Absorbance
Subvisible particules	Dynamic Light Scattering	<1µm particles population

56
57 **Table 2 : Orthogonal analysis for Critical Quality Attributes of Monoclonal Antibodies.** This
58 table summarizes the critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and the
59 methods used to assess them. SEC n-MS was used to assess aggregation/degradation and to
60 identify post-translational modifications (PTMs), while RPLC-MS was used to detect glycovariants
61 and analyze deamidation, oxidation, and disulfide bonds. Turbidity was assessed using UV/visible
62 spectrophotometry to measure absorbance, and subvisible particles were analyzed using dynamic
63 light scattering to determine the population of particles less than 1 µm in size
64

		Fc/2 - K + 2*oxidation	Fc/2 + oxidation	Fc/2 - K + oxidation	Fc/2	Fc/2 -K	Fc/2 - K - G0F	LC	LC*	LC + PyroGlu	Fd + oxidation	Fd	Fd*	Fd + PyroGlu + oxidation	Fd + PyroGlu	Fd + PyroGlu*
ATEZOLIZUMAB	Mass (Da)	nd	nd	23,763.6 ± 0.2	23,875.8 ± 0.4	23,747.6 ± 0.3	nd	23,364.8 ± 0.2	nd	nd	25,115.0 ± 0.4	25,098.9 ± 0.3	nd	nd	25,080.8 ± 0.5	nd
	PTS	nd	nd	1%	4%	95%	nd	100%	nd	nd	1%	97%	nd	nd	2%	nd
	Reference mAb	nd	nd	3%	5%	92%	nd	100%	nd	nd	2%	95%	nd	nd	3%	nd
	T° stressed	nd	nd	3%	3%	94%	nd	100%	nd	nd	5%	88%	nd	nd	7%	nd
AVELUMAB	Mass (Da)	nd	nd	nd	25,332.0 ± 0.2	25,203.8 ± 0.2	nd	22,788.8 ± 0.2	nd	nd	nd	25,256.2 ± 0.4	nd	nd	25,238.2 ± 0.2	nd
	PTS	nd	nd	nd	24%	76%	nd	100%	nd	nd	nd	98%	nd	nd	2%	nd
	Reference mAb	nd	nd	nd	25%	75%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd
	T° stressed	nd	nd	nd	29%	71%	nd	100%	nd	nd	nd	94%	nd	nd	6%	nd
BEVACIZUMAB	Mass (Da)	25,268.0 ± 0.2	nd	25,252.1 ± 0.2	nd	25,235.9 ± 0.4	23,791.2 ± 0.2	23,450.7 ± 0.3	nd	nd	25,961.9 ± 0.4 [+ Fd]	25,945.8 ± 0.4	nd	nd	25,927.8 ± 0.2	nd
	PTS	nd	nd	1%	nd	98%	1%	100%	nd	nd	1%	97%	nd	nd	2%	nd
	Reference mAb	nd	nd	1%	nd	97%	2%	100%	nd	nd	1%	97%	nd	nd	2%	nd
	T° stressed	2%	nd	3%	nd	87%	8%	100%	nd	nd	4%	88%	nd	nd	8%	nd
CETUXIMAB	Mass (Da)	nd	25,380.3 ± 0.4	25,252.1 ± 0.2	25,364.1 ± 0.2	25,236.0 ± 0.4	nd	23,426.6 ± 0.3	nd	nd	27,547.3 ± 0.3 <i>Highly glycosylated V_H domain / coelution of species. The main one is identified by the following structure : "Fd + PyroGlu + H7N4F1"</i>					
	PTS	nd	nd	nd	24%	76%	nd	100%	nd	nd						
	Reference mAb	nd	nd	nd	25%	75%	nd	100%	nd	nd						
	T° stressed	nd	1%	30% (coelution)		69%	nd	100%	nd	nd						
DURVALUMAB	Mass (Da)	nd	nd	25,241.9 ± 0.3	nd	25,226.6 ± 0.1	nd	23,578.0 ± 0.1	nd	23,559.6 ± 0.2	nd	25,707.6 ± 0.1	nd	nd	25,689.2 ± 0.2	nd
	PTS	nd	nd	2%	nd	98%	nd	98%	nd	2%	nd	97%	nd	nd	3%	nd
	Reference mAb	nd	nd	3%	nd	97%	nd	98%	nd	2%	nd	97%	nd	nd	3%	nd
	T° stressed	nd	nd	5%	nd	95%	nd	96%	nd	4%	nd	82%	nd	nd	18%	nd
IPILIMUMAB	Mass (Da)	nd	nd	25,219.7 ± 0.3	nd	25,203.8 ± 0.2	nd	23,454.7 ± 0.1	nd	23,436.6 ± 0.3	nd	25,386.4 ± 0.2	nd	25,385.3 ± 0.5	25,370.1 ± 0.1	nd
	PTS	nd	nd	2%	nd	98%	nd	97%	nd	3%	nd	7%	nd	1%	92%	nd
	Reference mAb	nd	nd	1%	nd	99%	nd	98%	nd	2%	nd	6%	nd	1%	93%	nd
	T° stressed	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	6%	nd	8%	86%	nd
NIVOLUMAB	Mass (Da)	25,251.6 ± 0.4	nd	25,235.9 ± 0.2	25,348.1 ± 0.3	25,220.0 ± 0.4	nd	23,373.5 ± 0.3	nd	23,355.5 ± 0.1	nd	nd	nd	24,565.2 ± 0.6	24,550.2 ± 0.2	nd

	PTS	1%	nd	3% (coelution)	96%	nd	95%	nd	5%	nd	nd	nd	1%	99%	nd	
	Reference mAb	1%	nd	3% (coelution)	96%	nd	93%	nd	7%	nd	nd	nd	1%	99%	nd	
	T° stressed	1%	nd	5% (coelution)	94%	nd	88%	nd	12%	nd	nd	nd	2%	98%	nd	
PANITUMUMAB	Mass (Da)	nd	nd	25,253.9 ± 0.3	25,366.2 ± 0.3 (+ [Fc/2 - K + oxidation])	25,238.1 ± 0.2	nd	23,357.6 ± 0.1	nd	nd	nd	24,918.6 ± 0.3	nd	nd	24,901.5 ± 0.2	nd
	PTS	nd	nd	1%	2%	97%	nd	100%	nd	nd	nd	21%	nd	nd	79%	nd
	Reference mAb	nd	nd	1%	2%	97%	nd	100%	nd	nd	nd	20%	nd	nd	80%	nd
	T° stressed	nd	nd	1%	3%	96%	nd	100%	nd	nd	nd	3%	nd	nd	97%	nd
PEMBROLIZUMAB	Mass (Da)	nd	nd	25,237.7 ± 0.2	nd	25,219.7 ± 0.3	nd	23,744.1 ± 0.4	nd	23,726.1 ± 0.2	nd	25,529.9 ± 0.3	nd	25,529.3 ± 0.3	25,513.2 ± 0.4	nd
	PTS	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	7%	nd	7%	86%	nd
	Reference mAb	nd	nd	3%	nd	97%	nd	96%	nd	4%	nd	4%	nd	5%	91%	nd
	T° stressed	nd	nd	3%	nd	97%	nd	93%	nd	7%	nd	1%	nd	8%	92%	nd
PERTUZUMAB	Mass (Da)	nd	nd	25,252.1 ± 0.3	nd	25,236.1 ± 0.4	nd	23,526.0 ± 0.2	nd	nd	nd	25,315.1 ± 0.4	nd	nd	25,297.0 ± 0.4	nd
	PTS	nd	nd	1%	nd	99%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd
	Reference mAb	nd	nd	3%	nd	97%	nd	100%	nd	nd	nd	97%	nd	nd	3%	nd
	T° stressed	nd	nd	12%	nd	88%	nd	100%	nd	nd	nd	94%	nd	nd	6%	nd
TRASTUZUMAB	Mass (Da)	nd	nd	25,252.0 ± 0.5	25,364.2 ± 0.3 (+ [Fc/2 - K + oxidation] + [Fc/2 - K])	25,236.0 ± 0.5	nd	23,442.9 ± 0.4	23,443.9 ± 0.3	23,425.8 ± 0.3	25,398.9 ± 0.2	25,383.1 ± 0.4	25,383.2 ± 0.3	nd	25,365.1 ± 0.2	25,365.3 ± 0.2
	PTS	nd	nd	1%	3%	96%	nd	92%	8% (coelution)		2%	96%	nd	nd	2%	nd
	Reference mAb	nd	nd	1%	3%	96%	nd	87%	13% (coelution)		2%	96%	nd	nd	2%	nd
	T° stressed	nd	nd	1%	2%	97%	nd	58%	20%	22% (+ [LC*])	1% (+ [Fd])	43%	44%	nd	2%	10%

65
66
67
68

Table 3 : Summary of the middle level rpLC-MS analysis on 11 mAbs

Relative absorbance (Mean +/- sd)	550nm			410nm			340nm		
	Control	Heat	Pneumatic	Control	Heat	Pneumatic	Control	Heat	Pneumatic
TRASTUZUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,02 (+/-0,03)	0 (+/-0)	0 (+/-0)	0,05 (+/-0,07)
ATEZOLIZUMAB	0,01 (+/-0,02)	0,07 (+/-0,1)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,08 (+/-0,11)	0 (+/-0)	0 (+/-0)
AVELUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,16 (+/-0,23)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,01 (+/-0,01)
BEVACIZUMAB	0,01 (+/-0,01)	0 (+/-0)	0,01 (+/-0,01)	0,01 (+/-0,01)	0 (+/-0)	0,02 (+/-0,01)	0,02 (+/-0,03)	0 (+/-0)	0,05 (+/-0,04)
CETUXIMAB	0 (+/-0)	0 (+/-0)	0,28 (+/-0,39)	0 (+/-0)	0 (+/-0)	0,03 (+/-0,05)	0 (+/-0)	0 (+/-0)	0,46 (+/-0,65)
DURVALUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0,06 (+/-0,08)	0 (+/-0)	0 (+/-0)
NIVOLUMAB	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)	0 (+/-0)
PANITUMUMAB	0,01 (+/-0,02)	0 (+/-0)	0,01 (+/-0,01)	0 (+/-0)	0 (+/-0)	0,01 (+/-0,01)	0,05 (+/-0,06)	0 (+/-0)	0,01 (+/-0,01)
PEMBROLIZUMAB	0,01 (+/-0,01)	0 (+/-0)	0,01 (+/-0,01)	0,01 (+/-0,01)	0,76 (+/-1,07)	0,01 (+/-0,02)	0,01 (+/-0,01)	0 (+/-0)	0,02 (+/-0,02)
PERTUZUMAB	0 (+/-0)	0,05 (+/-0,08)	0 (+/-0)	0 (+/-0)	0,07 (+/-0,1)	0 (+/-0)	0,03 (+/-0,04)	0,12 (+/-0,17)	0 (+/-0)

70

71

Table 4 : Summary of turbidity analysis on 10 mAbs. Relative absorbance (Mean +/- sd) at 550nm, 410nm, and 340nm tested under different conditions. Control represents mAbs in their native state, Heat represents mAbs subjected to thermal stress, and Pneumatic represents mAbs subjected to pneumatic stress. The relative absorbance was measured using a UV/visible spectrophotometer at each wavelength.

74

75

76